All News Kancera AB

Equities

KAN

SE0015658570

Market Closed - Nasdaq Stockholm Other stock markets 11:29:30 2024-05-17 am EDT			5-day change	1st Jan Change
1.71 ^SEK	+1.79%		-0.70%	-62.38%

May. 08	Kancera AB Announces Executive Changes	CI
May. 03	Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Interim Report First Quarter 2024, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851	May. 17	AQ
Kancera provides operational update regarding the KANDOVA study and reports increased patient recruitment	May. 16	AQ
Kancera appoints new Chief Scientific Officer and extends management team	May. 08	AQ
Kancera AB Announces Executive Changes	May. 08	CI
Kancera meets the primary objectives of the KAND145 clinical phase I study	May. 03	AQ
Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects	May. 03	CI
Kancera announces the outcome of the company's rights issue	Mar. 20	AQ
Kancera publishes prospectus in connection with the company’s rights issue	Mar. 01	AQ
Kancera resolves on a rights issue of approximately SEK 121.9 million	Feb. 23	AQ
Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851	Feb. 23	AQ
Kancera signs license agreement and obtains global commercial rights to the results from the FRACTAL study	Feb. 23	AQ
Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Kancera AB Signs A License Agreement with the University of Newcastle	Feb. 23	CI
Kancera AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Kancera presents the statistical analysis of top line data from the FRACTAL study	Feb. 06	AQ
Kancera AB Presents the statistical Analysis of Top Line Data from the FRACTAL Study	Feb. 06	CI
Kancera reports positive top line results from the FRACTAL study	Dec. 20	AQ
Kancera AB Reports Positive Top Line Results from the FRACTAL Study	Dec. 20	CI
Kancera provides operational update in connection with release of financial interim report for third quarter 2023	Nov. 17	AQ
Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851	Nov. 17	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Kancera AB

Equities

KAN

SE0015658570

All News

Filters